Combination immunotherapy with anti-CTLA4 checkpoint blockade, CpG, and anti-CD40 treatment led to regression of established syngeneic NBL tumors in the 9464D-C57BL/6 model, induced immunologic memory that protected against tumor re-challenge, and led to lower prevalence of Treg cells and higher CD8:Treg ratio in the TME (54). This evidence concerns the gene CTLA4 and neoplasm.